Navigation Links
Champions Oncology Reports Fiscal 2012 First Quarter Financial Results
Date:9/13/2011

overcome the impact of the price decreases.  These decreases were partially offset by an increase in sequencing revenue over the prior year first quarter.

Cost of POS for the first quarter of 2012 was $0.48 million which resulted in a gross margin of 20% as compared to 71% in the corresponding 2011 fiscal quarter.  The decrease in gross margin can be attributed to declines in pricing.

Research and development ("R&D") expenses for the first quarter of fiscal 2012 were $0.54 million as compared to $0.92 million in the first quarter of fiscal 2011.  The decrease from 2011 to 2012 was primarily related to lower spending on our technology platform and tumorgraft testing on the in-licensed compounds.

Sales and marketing expenses for first quarter of fiscal 2012 were $0.69 million as compared to $0.13 million in the first quarter of fiscal 2011.  The increase is primarily related to the increase in Company sales force personnel and increased marketing and promotional expenses.

General and administrative expenses for first quarter of fiscal 2012 were $1.72 million as compared to $0.60 million in the first quarter of fiscal 2011.  The increase is primarily related to the increase in Company personnel due to growth and stock-based compensation.

For the first quarter of fiscal 2012, the Company reported a net loss of $2.04 million, or ($0.04) per share, compared to a net loss of $0.59 million, or ($0.02) per share, in the corresponding quarter of fiscal 2011.  In addition to the factors described above, the Company's net losses reflect non-cash expenses, i.e., share-based compensation and depreciation, of $1.04 million or ($0.02) per share, in the first quarter of 2012 compared to $0.18 million, or ($0.01) per share, in the first quarter of 2011.

The Company's cash position on July 31, 2011 was $8.84 million.

* Non-GAAP Financial InformationSee the attached Reconciliation of GAAP Net Loss t
'/>"/>

SOURCE Champions Oncology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Five Californians Selected as Breakaway from Cancer® Champions to be Honored During Amgen Tour of California
2. Champions Biotechnology Exercises Option to License Proprietary Compound Based on Successful Tumorgraft™ Test Results
3. Champions CFO Resigns
4. Champions Biotechnology Awarded $1.46 million in Grants
5. Champions Biotechnology Announces Agreement With Cephalon for the Evaluation of a Novel Oncology Compound Using Predictive Biomerk Tumorgraft™ Platform
6. Higher Education Leaders Receive TCWF Champions of Health Professions Diversity Award
7. Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results
8. Champions Biotechnology, Inc. Signs Exclusive Licensing Agreement with Ramot for TAR-1, a Novel Therapeutic for the Treatment of Cancer
9. U.S. Patent Issued for Champions Biotechnologys Lead Oncology Drug
10. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
11. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014 Reportlinker.com announces ... in its catalogue: Global Animal Health ... About Animal Health Animal health refers ... or treat animals to enhance their quality of ... of animal food. The Global Animal Health market ...
(Date:8/27/2014)... Kewaunee Scientific Corporation (Nasdaq: KEQU ... quarterly cash dividend by 9% to twelve cents per ... with the dividend payable on September 22, 2014 to ... September 8, 2014. About Kewaunee Scientific ... Corporation is a recognized global leader in the design, ...
(Date:8/27/2014)... , Aug. 27, 2014  UBM Medica US announces ... online community for medical imaging professionals, presents special reporting ... Medical Imaging Management,s 2014 Annual Meeting . ... , 11 Principles of Successful Labor ... to greater profitability. , Why Don,t Patients ...
Breaking Medicine Technology:Global Animal Health Market 2014-2018 2Global Animal Health Market 2014-2018 3Global Animal Health Market 2014-2018 4Global Animal Health Market 2014-2018 5Global Animal Health Market 2014-2018 6Global Animal Health Market 2014-2018 7Diagnostic Imaging Covers Association for Medical Imaging Management (AHRA) 2014 Meeting 2Diagnostic Imaging Covers Association for Medical Imaging Management (AHRA) 2014 Meeting 3
... and INDIANAPOLIS, Ind., May 5 A new substudy from ... showed that patients who took prasugrel and had a reduced ... risk of cardiovascular death, heart attack or stroke compared with ... were published online in Circulation on May 4, ...
... Oramed Pharmaceuticals, Inc.,(OTC: ORMP) ( http://www.oramed.com ), a ... clinical trials will commence this week on 30 ... evaluate the safety,tolerability and efficacy of its oral ... (CRO) located in Johannesburg,South Africa, will oversee the ...
Cached Medicine Technology:New Analysis Evaluated Impact of Genetic Variation on Response to Prasugrel 2New Analysis Evaluated Impact of Genetic Variation on Response to Prasugrel 3New Analysis Evaluated Impact of Genetic Variation on Response to Prasugrel 4New Analysis Evaluated Impact of Genetic Variation on Response to Prasugrel 5Oramed Pharmaceuticals Announces Launch of Phase 2B Clinical Trials in South Africa of its Oral Insulin Capsule 2
(Date:8/27/2014)... last things a parent wants to deal with, but ... a week old. , Skin that turns yellow can ... and isn,t adequately eliminating the chemical bilirubin. But that ... left untreated can harm a baby. , University of ... that checks for jaundice in newborns and can deliver ...
(Date:8/27/2014)... last time you experienced worrisome medical symptoms, did ... health-care professional? If so, you,re not alone. Consumers ... peer support groups to gather anecdotal information and ... and trustworthy sources. New research to be presented ... studies the characteristics of consumers who use the ...
(Date:8/27/2014)... 2014 For nearly two decades, audiences ... beloved mantra singers Deva Premal & Miten with their ... of their latest album in May, their 2014 MANTRAS ... countries around the globe, including Russia, Ukraine, Israel, Australia, ... Europe. With a new album and a new five-piece ...
(Date:8/27/2014)... BESLER Consulting , a leading provider ... is pleased to announce that it has been named ... Companies. The list represents the most comprehensive look at ... , "It's been an exciting year for our company ... year's Inc. 5000 list,” said Jonathan Besler, BESLER’s President ...
(Date:8/27/2014)... Home Care Assistance of Scottsdale , a ... to announce the next installment in its renowned Healthy ... Suzanne Steinbaum, attending cardiologist and Director of Women’s Heart ... National Spokesperson for the American Heart Association’s Go Red ... surrounding women and heart disease, what heart disease is ...
Breaking Medicine News(10 mins):Health News:New smartphone app can detect newborn jaundice in minutes 2Health News:New smartphone app can detect newborn jaundice in minutes 3Health News:Educated consumers more likely to use potentially unreliable online healthcare information 2Health News:Deva Premal & Miten's Mantras For Life Tour Announced 2Health News:Deva Premal & Miten's Mantras For Life Tour Announced 3Health News:BESLER Consulting Among America’s Fastest Growing Private Companies 2Health News:Home Care Assistance of Scottsdale to Host Webinar on Heart Health, Featuring Dr. Suzanne Steinbaum 2Health News:Home Care Assistance of Scottsdale to Host Webinar on Heart Health, Featuring Dr. Suzanne Steinbaum 3
... the most comprehensive analyses yet done of the ancient history ... is not only native to the New World, but it ... evolved through birds and monkeys. The findings, presented ... researchers from Oregon State University, are based on the study ...
... HealthDay Reporter , WEDNESDAY, Nov. 2 (HealthDay News) -- Obese ... going about it in the most healthy or effective ways, ... teens trying to drop the pounds don,t seem to ... of nearly 44,000 adolescents who participated in the Philadelphia ...
... of the population of Denmark. The figure has been on ... Copenhagen Prospective Studies on Asthma in Childhood (COPSAC), University of ... "In our study of over 400 children we ... in their rectums and the risk of development of allergic ...
... Cancer cells maintain their life-style of extremely rapid growth and ... that alters the cells, ability to metabolize glucose a ... Krainer, Ph.D., and his team at Cold Spring Harbor Laboratory ... cells to regain the metabolism of normal cells, have discovered ...
... at Wayne State University,s Parent Health Lab in the ... that identifies women at risk for drug use by ... use itself. In phase I testing, this new screener ... at detecting recent drug use. The team of researchers ...
... combined with physical activity can help to improve some of ... The study, which is published online in the European ... can have on obese people with sleep apnoea, compared to ... syndrome (OSAS) causes frequent pauses of breathing to occur during ...
Cached Medicine News:Health News:Analysis reveals malaria, other diseases as ancient, adaptive and persistent foes 2Health News:Analysis reveals malaria, other diseases as ancient, adaptive and persistent foes 3Health News:Overweight Teens Don't Seem to Grasp Weight Loss Rules 2Health News:Overweight Teens Don't Seem to Grasp Weight Loss Rules 3Health News:Dirt prevents allergy 2Health News:Study reveals details of alternative splicing circuitry that promotes cancer's Warburg effect 2Health News:Wayne State creating computer-based drug intervention for at-risk post-partum women 2Health News:Mediterranean diet and exercise can reduce sleep apnea symptoms 2
... (Penicillin G) inhibits bacterial ... synthesis. Streptomycin belongs to ... inhibits bacterial growth by ... is used for prevention ...
...
Contains 10,000 units of penicillin (base), 10,000 g of streptomycin (base), and 25 g of amphotericin B/ml utilizing penicillin G (sodium salt), streptomycin sulfate, and amphotericin B as Fungizone ...
All BioWhittaker Cell Culture Reagent and Buffer products are manufactured in accordance with cGMP regulations and are cell culture tested to assure compatibility. , Typical Properties, Sterility : ...
Medicine Products: